BioFreedom US IDE Feasibility Trial

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2/PHASE3

Total Enrollment

72 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-08-31

Study Completion Date

2019-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to collect additional safety and effectiveness data for on the Biosensors BioFreedom™ BA9 Drug Coated Coronary Stent in patients with native, de novo coronary artery disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

LEADERS FREE II: BioFreedom™ Pivotal Study

NCT02843633

Acute Coronary Syndrome High Bleeding Risk

ACTIVE_NOT_RECRUITING NA

Biofreedom Prospective Multicenter Observational Registry

NCT03045848

Coronary Artery Disease Aggravated Myocardial Ischemia Myocardial Infarction

TERMINATED

BioFreedom™ BA9™ Ultra

NCT05331547

Cardiovascular Death Myocardial Infarction Revascularization

UNKNOWN

Leaders Free III: BioFreedom™ Clinical Trial

NCT03118895

Cardiac Death Myocardial Infarction Stent Thrombosis +2 more

COMPLETED NA

BioFreedom French Registry

NCT03745066

Coronary Artery Disease

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a multi-center prospective trial of 100 patients at up to 15 centers. The study population will consist of patients preventing with symptomatic ischemic heart disease due to de novo stenotic lesion(s) in native coronary artery(ies) with reference vessel diameter between 2.25 mm and 4.0 mm.

The primary safety endpoint for this clinical trial is the occurrence of major adverse cardiac events (MACE) defined as the composite of cardiac death, myocardial infarction, target lesion revascularization and academic research consortium (ARC) definite stent thrombosis within 9 months following the implantation.

The primary effectiveness endpoint for this trial is in-stent late lumen loss at 9 months as compared to historical control

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ischemic Heart Disease Stable Angina Unstable Angina Silent Ischemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

BioFreedom

Group Type EXPERIMENTAL

BioFreedom drug coated coronary stent

Intervention Type DEVICE

Placement of a BioFreedom drug coated stent in a narrow coronary artery

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

BioFreedom drug coated coronary stent

Placement of a BioFreedom drug coated stent in a narrow coronary artery

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Individual is ≥ 18 years of age
* Individual must have clinical evidence if ischemic heart disease, stable or unstable angina, silent ischemia, or a positive functional study;
* Individual must be an acceptable candidate for percutaneous coronary intervention (PCI), stenting, and emergent coronary artery bypass graft (CABG) surgery
* Individual is competent and willing to provide informed consent to participate in the trial

Exclusion Criteria

* A known hypersensitivity or contraindication to aspirin, heparin, clopidogrel, or a sensitivity to contrast media that cannot be adequately pre-medicated;
* History or known allergic reaction or significant sensitivity to drugs similar to BA9;
* A platelet count \< 100,000 cells/mm3 or \> 700,000 cells/mm3, or a WBC \< 3,000 cells/mm3;
* A creatinine level \> 2.5 mg/dL;
* Evidence of an acute myocardial infarction with 72 hours of the intended stenting (defined as: Q wave or non-Q wave myocardial infarction having a Troponin either I or T pre-procedure elevated above the Institution's upper limit of normal);
* Previous or planned PCI of any vessel within 30 days pre or post procedure;
* Patient unable to take clopidogrel for 3 months or patient who have comorbidities that would prohibit the cessation of clopidogrel at 3 months;
* Planned adjunctive treatment during the intended stenting (eg balloon valvuloplasty, percutaneous endovascular intervention, etc)
* During the intended or index procedure the target lesion(s) requires treatment with a device other than a plain old balloon prior to stent placement (such as, but not limited to, cutting balloon, directional atherectomy, excimer laser, rotational atherectomy, thrombectomy, etc);
* History of documented prior stroke within 6 months of the intended procedure;
* Active peptic ulcer or upper gastrointestinal bleeding documented within the prior 6 months;
* History of active bleeding diathesis or coagulopathy or will refuse blood transfusion;
* Individual is pregnant, nursing or planning to be pregnant;
* Any previous or planned treatment of the target vessel(s) with anti-restenotic therapies including, but not limited to brachytherapy;
* Concurrent medical condition with a life expectancy of less than 12 months or individual has any serious medical condition, which in the opinion of the investigator, may adversely affect the safety and/or effectiveness of the participant or the study;
* Individual is currently enrolled in another investigational drug or device trial. If, however, if investigational trial device or drug becomes commercially available, these trials are not considered investigational;
* Previous ACS within 9 months of pre or post procedure

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No